| 1. |
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
|
| 2. |
張小賀. 阿奇霉素聯合細菌溶解產物對慢阻肺合并支氣管擴張疾病的臨床效果. 唐山: 華北理工大學, 2023.
|
| 3. |
Lewis PO. Risk factor evaluation for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in community-acquired pneumonia. Ann Pharmacother, 2021, 55(1): 36-43.
|
| 4. |
中華醫學會呼吸病學分會感染學組. 中國銅綠假單胞菌下呼吸道感染診治專家共識(2022 年版). 中華結核和呼吸雜志, 2022, 45(8): 739-752.
|
| 5. |
Pisa D, Alonso R, Carrasco L. Parkinson’s disease: a comprehensive analysis of fungi and bacteria in brain tissue. Int J Biol Sci, 2020, 16(7): 1135-1152.
|
| 6. |
Maggiorelli C, Di Pierro I, Manta C, et al. Nocardia and lungs in COPD: beyond immuno-deficiencies. COPD, 2015, 12(3): 315-319.
|
| 7. |
劉艷紅, 韋曉山, 蘇遠, 等. 蓋爾森基興諾卡菌致肺部感染病例 1 例. 臨床醫學進展, 2024, 14(5): 68-72.
|
| 8. |
李柔, 楊斌, 曾憲春, 等. 支氣管擴張癥合并銅綠假單胞菌感染: 2012-2022 年的文獻計量學分析及可視化研究. 中國感染與化療雜志, 2024, 24(1): 8-18.
|
| 9. |
Martínez-García Má, Faner R, Oscullo G, et al. Risk factors and relation with mortality of a new acquisition and persistence of Pseudomonas aeruginosa in COPD patients. COPD, 2021, 18(3): 333-340.
|
| 10. |
Qin SG, Xiao W, Zhou CM, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther, 2022, 7(1): 199.
|
| 11. |
Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore), 2004, 83(5): 300-313.
|
| 12. |
劉俊楓, 周偉, 高鵬, 等. 甘肅省 10 例諾卡菌病患者的臨床特征. 中國感染控制雜志, 2022, 21(7): 661-667.
|
